The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
Rita AlaggioCatalina AmadorIoannis AnagnostopoulosAyoma D AttygalleIguaracyra Barreto de Oliveira AraujoEmilio BertiGovind BhagatAnita Maria BorgesDaniel BoyerMariarita CalaminiciAmy ChadburnJohn K C ChanWah CheukWee-Joo ChngJohn Kim ChoiShih-Sung ChuangSarah E CouplandMagdalena CzaderSandeep S DaveDaphne de JongMing-Qing DuKojo S J Elenitoba-JohnsonJudith A FerryJulia T GeyerDita A GratzingerJoan GuitartSumeet GujralMarian H HarrisChristine J HarrisonSylvia HartmannAndreas HochhausPatty M JansenKennosuke KarubeWerner KempfJoseph D KhouryHiroshi KimuraWolfram KlapperAlexandra Elizabeth KovachShaji K KumarAlexander J F LazarStefano LazziLorenzo LeonciniNelson R LeungVasiliki LeventakiXiao-Qiu LiMegan S LimWei-Ping LiuAbner LouissaintAndrea N MarcoglieseL Jeffrey MedeirosMichael MichalRoberto N MirandaChristina MitteldorfSantiago Montes MorenoWilliam George MoriceValentina NardiKikkeri N NareshYasodha NatkunamSiok Bian NgIlske OschliesGerman OttMarie-Cécile ParrensMelissa PulitzerSundararajan Vincent RajkumarAndrew C RawstronKaren L RechAndreas RosenwaldJonathan W SaidClémentine SarkozyShahin SayedCaner SayginAnna SchuhWilliam A SewellReiner SiebertAliyah R SohaniReuben M ToozeAlexandra Traverse-GlehenFrancisco VegaBeatrice VergierAshutosh D WechalekarBrent WoodLuc XerriWenbin XiaoPublished in: Leukemia (2022)
We herein present an overview of the upcoming 5 th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4 th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5 th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.